ES2133271T3 - Receptores para factores de crecimiento de fibroblastos. - Google Patents

Receptores para factores de crecimiento de fibroblastos.

Info

Publication number
ES2133271T3
ES2133271T3 ES90911235T ES90911235T ES2133271T3 ES 2133271 T3 ES2133271 T3 ES 2133271T3 ES 90911235 T ES90911235 T ES 90911235T ES 90911235 T ES90911235 T ES 90911235T ES 2133271 T3 ES2133271 T3 ES 2133271T3
Authority
ES
Spain
Prior art keywords
growth factor
fibroblast growth
fgf
receptor
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911235T
Other languages
English (en)
Inventor
Lewis T Williams
Daniel E Johnson
Pauline E Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2133271T3 publication Critical patent/ES2133271T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

SE HA PURIFICADO UN RECEPTOR PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS (FGF) QUE INCLUYE UN RECEPTOR PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS. SE HAN IDENTIFICADO VARIAS FORMAS ENTRE LAS QUE CABE INCLUIR FORMAS SOLUBLES QUE NO TIENEN NINGUN SEGMENTO DE TRANSMEMBRANA. SE HAN AISLADO Y SECUENCIADO LAS SECUENCIAS DE ADN QUE CODIFICAN A LOS RECEPTORES PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE FIBRAS DE LONGITUD TOTAL Y POLIPEPTIDOS QUE CONTIENEN UNA PARTE DE UN DOMINIO ENLAZADOR DE UN LIGANDO DEL FGF-R. ESTOS ADNS INCLUYEN ADNS QUE CODIFICAN UN FGF-R BASICO Y UN FGF-R HUMANO Y SON ENLAZADOS DE MANERA QUE SEAN CAPACES DE FUNCIONAR PARA CONTROLAR LAS SECUENCIAS Y EXTRESADOS EN UN CULTIVO DE UN HUESPED COMPATIBLE TRANSFORMADO, TRANSFECTADO O ELECTROACTIVADO POR UN VEHICULO DE CLONACION QUE CONTIENE LA SECUENCIA DE ADN. LA INVENCION TAMBIEN SE REFIERE A ANTICUERPOS PARA EL RECEPTOR, METODOS PARA SINTETIZAR LAS PROTEINAS DEL RECEPTOR PARA EL FACTOR DE CRECIMIENTO, METODOS PARA PROPORCIONAR ANALOGOS DE LOS RECEPTORES PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS. TAMBIEN SE DESCRIBEN LOS METODOS PARA EVALUAR LAS COMPOSICIONES QUE PROMUEVEN O INHIBEN LOS FACTORES DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS QUE SON AGONISTICOS O ANTAGONISTICOS A LOS RECEPTORES PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS. SE DESCRIBEN LOS USOS TERAPEUTICOS Y DE DIAGNOSTICO.
ES90911235T 1989-07-06 1990-07-06 Receptores para factores de crecimiento de fibroblastos. Expired - Lifetime ES2133271T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37700389A 1989-07-06 1989-07-06

Publications (1)

Publication Number Publication Date
ES2133271T3 true ES2133271T3 (es) 1999-09-16

Family

ID=23487374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911235T Expired - Lifetime ES2133271T3 (es) 1989-07-06 1990-07-06 Receptores para factores de crecimiento de fibroblastos.

Country Status (15)

Country Link
US (4) US6384191B1 (es)
EP (1) EP0481000B1 (es)
JP (1) JP3039802B2 (es)
KR (1) KR100235266B1 (es)
AT (1) ATE179862T1 (es)
AU (1) AU638734B2 (es)
CA (1) CA2063431C (es)
DE (1) DE69033109T2 (es)
DK (1) DK0481000T3 (es)
ES (1) ES2133271T3 (es)
FI (1) FI920027A0 (es)
HU (1) HU215581B (es)
NO (1) NO310032B1 (es)
SG (1) SG72657A1 (es)
WO (1) WO1991000916A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
CA2063431C (en) 1989-07-06 2002-10-29 Lewis T. Williams Receptors for fibroblast growth factors
JP2552942B2 (ja) * 1990-06-01 1996-11-13 三井東圧化学株式会社 ヒトｂーＦＧＦ受容体遺伝子
ATE243253T1 (de) * 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H Rezeptoren der wachstumsfaktoren aus fibroblasten
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
ES2091018T3 (es) * 1992-06-18 1996-10-16 Whittier Inst Diabetes & Endoc Procedimiento para la deteccion de enfermedades neoplasicas.
CA2145985C (en) * 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
AU3170499A (en) * 1998-04-28 1999-11-16 Eisai Co. Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20020192719A1 (en) * 1998-09-30 2002-12-19 Caliper Technologies Corp. Homogeneous assay methods
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
BR0010524A (pt) * 1999-05-14 2002-05-28 Imclone Systems Inc Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US6812221B2 (en) 2000-11-21 2004-11-02 The Texas A&M University System FGF-affinity chromatography
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1340507B1 (de) * 2002-02-28 2004-09-22 Switch Biotech Aktiengesellschaft Verwendung eines Fibroblastenwachstumsfaktor-Bindeproteins zur Behandlung und Diagnose von diabetischen Wundheilugnsstörungen
AU2003212293A1 (en) * 2002-02-28 2003-09-09 Switch Biotech Ag Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
US20060281130A1 (en) 2002-12-20 2006-12-14 Elisabeth Bock Metod of modulation of interaction between receptor and ligand
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
MX2010008874A (es) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
BRPI0916904A2 (pt) * 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
ES2523740T3 (es) * 2008-11-07 2014-12-01 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
CA2754163C (en) 2009-03-25 2019-04-09 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
US8614183B2 (en) 2009-11-13 2013-12-24 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
MX2012013068A (es) 2010-05-11 2013-03-05 Aveo Pharmaceuticals Inc Anticuerpos anti - fgfr2.
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
AU2012318247B2 (en) 2011-11-14 2015-12-17 Five Prime Therapeutics, Inc. Methods of treating cancer
EP4036118A1 (en) 2013-08-01 2022-08-03 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
JP6851965B2 (ja) 2014-09-26 2021-03-31 サハイ バートナガール ラジェンドラ 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP6952685B2 (ja) 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント
RU2021107536A (ru) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
BR112023002455A2 (pt) 2020-08-21 2023-03-28 Genzyme Corp Anticorpos fgfr3 e métodos de uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
US4668476A (en) * 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2063431C (en) * 1989-07-06 2002-10-29 Lewis T. Williams Receptors for fibroblast growth factors
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6022741A (en) * 1997-03-13 2000-02-08 University Of North Carolina At Chapel Hill Regulatory genetic DNA that regulates the Class II transactivator (CIITA)

Also Published As

Publication number Publication date
NO920060D0 (no) 1992-01-03
DE69033109D1 (de) 1999-06-17
US6350593B1 (en) 2002-02-26
HUT61052A (en) 1992-11-30
KR100235266B1 (en) 1999-12-15
WO1991000916A2 (en) 1991-01-24
NO920060L (no) 1992-03-02
US6355440B1 (en) 2002-03-12
CA2063431A1 (en) 1991-01-07
JPH04506604A (ja) 1992-11-19
ATE179862T1 (de) 1999-05-15
AU6077990A (en) 1991-02-06
US5707632A (en) 1998-01-13
US6384191B1 (en) 2002-05-07
JP3039802B2 (ja) 2000-05-08
HU215581B (hu) 1999-01-28
CA2063431C (en) 2002-10-29
EP0481000A1 (en) 1992-04-22
FI920027A0 (fi) 1992-01-03
EP0481000A4 (en) 1992-10-21
HU906195D0 (en) 1992-06-29
DE69033109T2 (de) 1999-11-18
NO310032B1 (no) 2001-05-07
SG72657A1 (en) 2000-05-23
WO1991000916A3 (en) 1991-10-17
EP0481000B1 (en) 1999-05-12
AU638734B2 (en) 1993-07-08
DK0481000T3 (da) 1999-11-15

Similar Documents

Publication Publication Date Title
ES2133271T3 (es) Receptores para factores de crecimiento de fibroblastos.
D'Andrea et al. Expression cloning of the murine erythropoietin receptor
EP0555989B1 (en) TGF-beta induced gene and protein
HIMMLER et al. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein
Tensen et al. Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3)
Kondo et al. Expression of functional human interleukin-2 receptor in mouse T cells by cDNA transfection
CA2076979C (en) Substantially pure transforming growth factor-.beta.-1-binding protein and nucleotide sequences expressing the binding protein
DE69638022D1 (de) Aus wirbeltieren und darauf basierende verfahren
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
BR9708518A (pt) Moduladores de fator associado a receptor tnf (traf) sua preparação e uso
KR20010074494A (ko) 피부세포에서 분리한 폴리뉴클레오티드와 이의 이용방법
WO2001036447A3 (en) Hormone receptor functional entities and methods of their use
WO2001075140A1 (en) HYBRID CYTOKINE OF IL-7 AND β-CHAIN OF HEPATOCYTE GROWTH FACTOR
NZ277389A (en) Bone morphogenetic protein (bmp) receptor kinase protein and dna, its production and use in identifying compounds which bind it
ES2134771T5 (es) Adn que codifica el receptor del factor estimulador de una colonia de granulocitos.
Kaplan et al. Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera
US5789237A (en) Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
EP0495674A2 (en) TGF-beta induced gene family
Too et al. Prolactin induces expression of FGF-2 and a novel FGF-responsive NonO/p54nrb-related mRNA in rat lymphoma cells
Goetschy et al. The Unglycosylated Extracellular Domain of Type‐II Receptor for Transforming Growth Factor‐β: A Novel Assay for Characterizing Ligand Affinity and Specificity
Axelrod et al. The interferon-gamma receptor extracellular domain. Non-identical requirements for ligand binding and signaling.
EP0490410B1 (en) TXA2 Receptor and gene encoding the same
Zhang et al. Amino acids 67 and 68 of transforming growth factor-β regulate binding to a glycosyl phosphatidyl inositol-linked membrane protein on vascular endothelial cells
Minamoto et al. Ligand-dependent selection of the receptor gene: segregation of IL-2 binding activity and anti-Tac reactivity by a single amino acid alteration in the Tac antigen (p55)
Kimberley et al. The HSPG binding domain of APRIL serves as a platform for ligand multimersation and cross-linking.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 481000

Country of ref document: ES